LABORATORY RESEARCH Chronic Variable Stress Activates Hematopoietic Stem Cells The authors showed that stress increases proliferation of these most primitive hematopoietic progenitors, giving rise to higher levels of disease-promoting inflammatory leukocytes. They found that chronic stress induced monocytosis and neutrophilia in humans. While investigating the source of leukocytosis in mice, they discovered that stress activates upstream hematopoietic stem cells. [Nat Med] Abstract | Editorial Altered Translation of GATA1 in Diamond-Blackfan Anemia Investigators identified mutations in GATA1, encoding the critical hematopoietic transcription factor GATA-binding protein-1, that reduce levels of full-length GATA1 protein and cause Diamond-Blackfan anemia in rare instances. [Nat Med] Abstract Purinergic P2Y14 Receptor Modulates Stress-Induced Hematopoietic Stem/Progenitor Cell Senescence Scientists demonstrate that P2Y14 modifies cell senescence and cell death in response to tissue stress, thereby enabling preservation of hematopoietic stem/progenitor cell function. [J Clin Invest] Full Article The Effects of Intestinal Tract Bacterial Diversity on Mortality following Allogeneic Hematopoietic Stem Cell Transplantation Investigators examined the impact of intestinal diversity on subsequent mortality outcomes following transplantation. Fecal specimens were collected from 80 recipients of allogeneic hematopoietic stem cell transplantation at the time of stem cell engraftment. [Blood] Abstract | Press Release Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myeloid Leukemia Using an in silico gene expression-based screen for compounds evoking transcriptional effects similar to the anti-leukemia stem cell agent parthenolide, investigators identified AR-42, a novel histone deacetylase inhibitor that is structurally similar to phenylbutyrate, but with improved activity at sub-micromolar concentrations. [Mol Cancer Ther] Abstract SL-401 and SL-501, Targeted Therapeutics Directed at the Interleukin-3 Receptor, Inhibit the Growth of Leukemic Cells and Stem Cells in Advanced Phase Chronic Myeloid Leukemia After confirming that interleukin-3 receptor (IL3R) is highly expressed on CD34+/CD38– BCR-ABL1+ chronic myeloid leukemia stem cells, researchers investigated whether targeting IL3R with diphtheria toxin-IL3 fusion proteins SL-401 and SL-501 could eradicate these stem cells. [Br J Haematol] Abstract A Stable and Reproducible Human Blood-Brain Barrier Model Derived from Hematopoietic Stem Cells Scientists describe a method to generate a human blood brain barrier (BBB) model using cord blood-derived hematopoietic stem cells. The cells were initially differentiated into endothelial cells followed by the induction of BBB properties by co-culture with pericytes. [PLoS One] Full Article TC1(C8orf4) Regulates Hematopoietic Stem/Progenitor Cells and Hematopoiesis Researchers report that Tc1 regulates hematopoiesis in mice. Myeloid and lymphoid cells are increased markedly in peripheral blood of Tc1-deleted mice compared to wild type controls. [PLoS One] Full Article CLINICAL RESEARCH Sequential Myeloablative Autologous Stem Cell Transplantation and Reduced Intensity Allogeneic Hematopoietic Cell Transplantation Is Safe and Feasible in Children, Adolescents and Young Adults with Poor Risk Refractory or Recurrent Hodgkin and Non-Hodgkin Lymphoma Investigators conducted a multi-center prospective study of myeloablative conditioning and autologous stem cell transplantation, followed by a reduced intensity conditioning and allogeneic hematopoietic cell transplantation in children, adolescents and young adults, with poor risk refractory or recurrent lymphoma. [Leukemia] Abstract Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis Researchers determined the effects of autologous nonmyeloablative hematopoietic stem cell transplantation in 65 individuals with new-onset Type 1 diabetes who were enrolled in two Chinese centers and one Polish center, pooled, and followed up for 48 months. [Diabetes] Abstract |